**Almond 2016** Almond LM, Mukadam S, Gardner I, Okialda K, Wong S, Hatley O, Tay S, Rowland-Yeo K, Jamei M, Rostami-Hodjegan A, Kenny JR. Prediction of Drug-Drug Interactions Arising from CYP3A induction Using a Physiologically Based Dynamic Model. Drug Metab Dispos. 2016 Jun;44(6):821-32.

**Guest 2011** Guest EJ, Aarons L, Houston JB, Rostami-Hodjegan A, Galetin A. Critique of the two-fold measure of prediction success for ratios: application for the assessment of drug-drug interactions. Drug Metab Dispos. 2011 Feb;39(2):170-3.

**OSP PK Database** (https://github.com/Open-Systems-Pharmacology/Database-for-observed-data)



## Cimetidine-Alfentanil-DDI

**Kienlen 1993** Kienlen, J., Levron, JC., Aubas, S. *et al.* Pharmacokinetics of Alfentanil in Patients Treated with Either Cimetidine or Ranitidine.  Drug Invest **6,** 257–262 (1993).



## Cimetidine-Alprazolam-DDI

**Pourbaix 1985** Pourbaix S, Desager JP, Hulhoven R, Smith RB, Harvengt C. Pharmacokinetic consequences of  long term coadministration of cimetidine and triazolobenzodiazepines,  alprazolam and triazolam, in healthy subjects. Int J Clin Pharmacol Ther Toxicol. 1985 Aug;23(8):447-51.

**Abernethy 1983**  Abernethy DR,  Greenblatt DJ, Divoll M, Moschitto LJ, Harmatz JS, Shader RI.  Interaction of cimetidine with the triazolobenzodiazepines alprazolam  and triazolam. Psychopharmacology (Berl). 1983;80(3):275-8. doi:  10.1007/BF00436169.



## Cimetidine-Midazolam-DDI

**Elliott 1984** Elliott P, Dundee  JW, Elwood RJ, Collier PS. The influence of H2 receptor antagonists on  the plasma concentrations of midazolam and temazepam. Eur J  Anaesthesiol. 1984 Sep;1(3):245-51.

**Fee 1987** Fee JP, Collier PS, Howard PJ, Dundee JW. Cimetidine and ranitidine increase midazolam  bioavailability. Clin Pharmacol Ther. 1987 Jan;41(1):80-4.

**Greenblatt 1986** Greenblatt DJ,  Locniskar A, Scavone JM, Blyden GT, Ochs HR, Harmatz JS, Shader RI.  Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. Anesth Analg. 1986 Feb;65(2):176-80.

**Martinez 1999** Martínez C, Albet  C, Agúndez JA, Herrero E, Carrillo JA, Márquez M, Benítez J, Ortiz JA.  Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2,  CYP2D6, and CYP3A by H2-receptor antagonists. Clin Pharmacol Ther. 1999  Apr;65(4):369-76.

**Salonen 1986** Salonen M, Aantaa  E, Aaltonen L, Kanto J. Importance of the interaction of midazolam and  cimetidine. Acta Pharmacol Toxicol (Copenh). 1986 Feb;58(2):91-5.



## Cimetidine-Triazolam-DDI

**Pourbaix 1985** Pourbaix S, Desager JP, Hulhoven R, Smith RB, Harvengt C. Pharmacokinetic consequences of  long term coadministration of cimetidine and triazolobenzodiazepines,  alprazolam and triazolam, in healthy subjects. Int J Clin Pharmacol Ther Toxicol. 1985 Aug;23(8):447-51.

**Abernethy 1983**  Abernethy DR,  Greenblatt DJ, Divoll M, Moschitto LJ, Harmatz JS, Shader RI.  Interaction of cimetidine with the triazolobenzodiazepines alprazolam  and triazolam. Psychopharmacology (Berl). 1983;80(3):275-8.

**Cox 1986** Cox SR, Kroboth PD, Anderson PH, Smith RB. Mechanism for the interaction between triazolam  and cimetidine. Biopharm Drug Dispos. 1986 Nov-Dec;7(6):567-75.

**Friedman 1988** Friedman H,  Greenblatt DJ, Burstein ES, Scavone JM, Harmatz JS, Shader RI. Triazolam kinetics: interaction with cimetidine, propranolol, and the  combination. J Clin Pharmacol. 1988 Mar;28(3):228-33.



## Cimetidine-Verapamil-DDI

**Smith 1984** Smith MS, Benyunes  MC, Bjornsson TD, Shand DG, Pritchett EL. Influence of cimetidine on  verapamil kinetics and dynamics. Clin Pharmacol Ther. 1984  Oct;36(4):551-4. 



## Clarithromycin-Midazolam-DDI

**Gorski 1998** Gorski, J. C., Jones, D. R., Haehner‐Daniels, B. D., Hamman, M. A., O'Mara Jr, E. M., & Hall, S. D. (1998). The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. *Clinical Pharmacology & Therapeutics*, *64*(2), 133-143.

**Gurley 2006** Gurley, B., Hubbard, M. A., Williams, D. K., Thaden, J., Tong, Y., Gentry, W. B., ... & Cheboyina, S. (2006). Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin. *The Journal of Clinical Pharmacology*, *46*(2), 201-213.

**Gurley 2008a** Gurley, B. J., Swain, A., Hubbard, M. A., Hartsfield, F., Thaden, J., Williams, D. K., ... & Tong, Y. (2008). Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo. *Clinical Pharmacology & Therapeutics*, *83*(1), 61-69.

**Markert 2013** Markert, C., Hellwig, R., Burhenne, J., Hoffmann, M. M., Weiss, J., Mikus, G., & Haefeli, W. E. (2013). Interaction of ambrisentan with clarithromycin and its modulation by polymorphic SLCO1B1. *European journal of clinical pharmacology*, *69*(10), 1785-1793.

**Prueksaritanont 2017** Prueksaritanont, T., Tatosian, D. A., Chu, X., Railkar, R., Evers, R., Chavez‐Eng, C., ... & Cai, X. (2017). Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A. *Clinical Pharmacology & Therapeutics*, *101*(4), 519-530.

**Quinney 2008** Quinney, S. K., Haehner, B. D., Rhoades, M. B., Lin, Z., Gorski, J. C., & Hall, S. D. (2008). Interaction between midazolam and clarithromycin in the elderly. *British journal of clinical pharmacology*, *65*(1), 98-109.

**van Dyk 2018** van Dyk, M., Marshall, J. C., Sorich, M. J., Wood, L. S., & Rowland, A. (2018). Assessment of inter-racial variability in CYP3A4 activity and inducibility among healthy adult males of Caucasian and South Asian ancestries. *European journal of clinical pharmacology*, *74*(7), 913-920.

**Yeates 1996** Yeates, R. A., Laufen, H., & Zimmermann, T. (1996). Interaction between midazolam and clarithromycin: comparison with azithromycin. *International journal of clinical pharmacology and therapeutics*, *34*(9), 400-405.



## Clarithromycin-Triazolam-DDI

**Greenblatt 1998a** Greenblatt DJ, von Moltke LL, Harmatz JS, Counihan M, Graf JA, Durol AL, Mertzanis P, Duan SX, Wright CE, Shader RI. Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. Clin Pharmacol Ther. 1998 Sep;64(3):278-85.



## Erythromycin-Alfentanil-DDI

**Bartkowski 1989** Bartkowski, R. R., Goldberg, M. E., Larijani, G. E., & Boerner, T. (1989). Inhibition of alfentanil metabolism by erythromycin. *Clinical Pharmacology & Therapeutics*, *46*(1), 99-102.

**Bartkowski 1993** Bartkowski, R. R., Goldberg, M. E., Huffnagle, S., & Epstein, R. H. (1993). Sufentanil disposition. Is it affected by erythromycin administration?. *Anesthesiology*, *78*(2), 260-265.



## Erythromycin-Alprazolam-DDI

**Yasui 1996** Yasui, N., Otani, K., Kaneko, S., Ohkubo, T., Osanai, T., Sugawara, K., ... & Ishizaki, T. (1996). A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism. *Clinical Pharmacology & Therapeutics*, *59*(5), 514-519.



## Erythromycin-Midazolam-DDI

**Carls 2014** Carls, A., Jedamzik, J., Witt, L., Hohmann, N., Burhenne, J., & Mikus, G. (2014). Systemic exposure of topical erythromycin in comparison to oral administration and the effect on cytochrome P450 3A4 activity. *British journal of clinical pharmacology*, *78*(6), 1433-1440.

**Okudaira 2007** Okudaira, T., Kotegawa, T., Imai, H., Tsutsumi, K., Nakano, S., & Ohashi, K. (2007). Effect of the treatment period with erythromycin on cytochrome P450 3A activity in humans. *The Journal of Clinical Pharmacology*, *47*(7), 871-876.

**Olkkola 1993** Olkkola, K. T., Aranko, K., Luurila, H., Hiller, A., Saarnivaara, L., Himberg, J. J., & Neuvonen, P. J. (1993). A potentially hazardous interaction between erythromycin and midazolam. *Clinical Pharmacology & Therapeutics*, *53*(3), 298-305.

**Swart 2002** Swart, E. L., van der Hoven, B., Johan Groeneveld, A. B., Touw, D. J., & Danhof, M. (2002). Correlation between midazolam and lignocaine pharmacokinetics and MEGX formation in healthy volunteers. *British journal of clinical pharmacology*, *53*(2), 133-139.

**Zimmermann 1996** Zimmermann, T., Yeates, R. A., Laufen, H., Scharpf, F., Leitold, M., & Wildfeuer, A. (1996). Influence of the antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam. *Arzneimittel-Forschung*, *46*(2), 213-217.



## Erythromycin-Triazolam-DDI

**Greenblatt 1998** Greenblatt, D. J., von Moltke, L. L., Harmatz, J. S., Counihan, M., Graf, J. A., Durol, A. L. B., ... & Shader, R. I. (1998). Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. *Clinical Pharmacology & Therapeutics*, *64*(3), 278-285.

**Phillips 1986** Phillips, J. P., Antal, E. J., & Smith, R. B. (1986). A pharmacokinetic drug interaction between erythromycin and triazolam. *Journal of clinical psychopharmacology*, *6*(5), 297-299.



## Fluconazole-Alfentanil-DDI

**Palkama 1998** Palkama, V. J., Isohanni, M. H., Neuvonen, P. J., & Olkkola, K. T. (1998). The effect of intravenous and oral fluconazole on the pharmacokinetics and pharmacodynamics of intravenous alfentanil. *Anesthesia & Analgesia*, *87*(1), 190-194.



## Fluconazole-Midazolam-DDI

**Ahonen 1997** Ahonen, J., Olkkola, K. T., & Neuvonen, P. J. (1997). Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam. *European journal of clinical pharmacology*, *51*(5), 415-419.

**Olkkola 1996** Olkkola, K. T., Ahonen, J., & Neuvonen, P. J. (1996). The effect of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. *Anesthesia & Analgesia*, *82*(3), 511-516.



## Fluconazole-Triazolam-DDI

**Varhe 1996** Varhe, A., Olkkola, K. T., & Neuvonen, P. J. (1996). Effect of fluconazole dose on the extent of fluconazole‐triazolam interaction. *British journal of clinical pharmacology*, *42*(4), 465-470.



## Fluvoxamine-Midazolam-DDI

**Kashuba 1998** Kashuba AD1, Nafziger AN, Kearns GL, Leeder JS, Gotschall R, Rocci ML Jr, Kulawy RW, Beck DJ, Bertino JS Jr. Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. Clin Pharmacol Ther. 1998 Sep;64(3):257-68.

**Lam 2003** Lam YW1, Alfaro CL, Ereshefsky L, Miller M. Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone. J Clin Pharmacol. 2003 Nov;43(11):1274-82.



## Fluvoxamine-Alprazolam-DDI

**Fleishaker 1994** Fleishaker, J. C., & Hulst, L. K. (1994). A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. *European journal of clinical pharmacology*, *46*(1), 35-39.



## Itraconazole-Alprazolam-DDI

**Yasui 1998** Yasui  N, Kondo T, Otani K, Furukori H, Kaneko S, Ohkubo T, Nagasaki T, Sugawara K.  Effect of itraconazole on the single oral dose pharmacokinetics and  pharmacodynamics of alprazolam. Psychopharmacology (Berl). 1998  Oct;139(3):269-73.



## Itraconazole-Midazolam-DDI

**Ahonen 1995** Ahonen J, Olkkola KT, Neuvonen PJ. Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers. Br J Clin Pharmacol. 1995 Sep;40(3):270-2.

**Backman 1998** Backman JT, Kivistö KT, Olkkola KT, Neuvonen PJ. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol. 1998 Mar;54(1):53-8.

**Olkkola 1994** Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther. 1994 May;55(5):481-5.

**Olkkola 1996** Olkkola KT, Ahonen J, Neuvonen PJ. The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg. 1996 Mar;82(3):511-6.

**Prueksaritanont 2017** Prueksaritanont T, Tatosian DA, Chu X, Railkar R, Evers R, Chavez-Eng C, Lutz R, Zeng W, Yabut J, Chan GH, Cai X, Latham AH, Hehman J, Stypinski D, Brejda J, Zhou C, Thornton B, Bateman KP, Fraser I,, Stoch SA. Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A. Clin Pharmacol Ther. 2017 Apr;101(4):519-530.

**Templeton 2010** Templeton I, Peng CC, Thummel KE, Davis C, Kunze KL, Isoherranen N. Accurate prediction of dose-dependent CYP3A4 inhibition by itraconazole and its metabolites from in vitro inhibition data. Clin Pharmacol Ther. 2010 Oct;88(4):499-505.

**Yu 2004** Yu KS, Cho JY, Jang IJ, Hong KS, Chung JY, Kim JR, Lim HS, Oh DS, Yi SY, Liu KH, Shin JG, Shin SG. Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. Clin Pharmacol Ther. 2004 Aug;76(2):104-12.



## Itraconazole-Triazolam-DDI

**Neuvonen 1996** Neuvonen PJ, Varhe A, Olkkola KT. The effect of ingestion time interval on the interaction between itraconazole and triazolam. Clin Pharmacol Ther. 1996 Sep;60(3):326-31.

**Varhe 1994** Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther. 1994 Dec;56(6 Pt 1):601-7.



## Verapamil-Midazolam-DDI

**Backman 1994** Backman JT, Olkkola KT, Aranko K, Himberg JJ, Neuvonen PJ. Dose of midazolam should be reduced during diltiazem and verapamil treatments. Br J Clin Pharmacol. 1994 Mar;37(3):221-5.

**Wang 2005** Wang Y,  Jin Y, Hilligoss  JK, Ho H, Hamman MA, Hu Z, Gorski JD, Hall SD. Effect of CYP3A5 genotype on the extent of CYP3A inhibition by verapamil. Clin Pharmacol Ther. 2005; 77(2):P3.



## Efavirenz-Alfentanil-DDI

**Kharasch 2012** Kharasch ED, Whittington D, Ensign D, Hoffer C, Bedynek PS, Campbell S, Stubbert K, Crafford A, London A, Kim T. Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2012 Apr;91(4):673-84.



## Efavirenz-Midazolam-DDI

**Katzenmaier 2010** Katzenmaier S, Markert C, Mikus G. Proposal of a new limited sampling strategy to predict CYP3A activity using a partial AUC of midazolam. Eur J Clin Pharmacol. 2010 Nov;66(11):1137-41.

**Mikus 2017** Mikus G, Heinrich T, Bödigheimer J, Röder C, Matthee AK, Weiss J, Burhenne J, Haefeli WE. Semisimultaneous Midazolam Administration to Evaluate the Time Course of CYP3A Activation by a Single Oral Dose of Efavirenz. J Clin Pharmacol. 2017 Jul;57(7):899-905.



## Rifampicin-Alfentanil-DDI

**Kharasch 1997** Kharasch ED, Russell M, Mautz D, Thummel KE, Kunze KL, Bowdle A, Cox K. The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. Anesthesiology. 1997 Jul;87(1):36-50.

**Kharasch 2004** Kharasch ED, Walker A, Hoffer C, Sheffels P. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. Clin Pharmacol Ther. 2004 Nov;76(5):452-66.

**Kharasch 2011** Kharasch ED, Francis A, London A, Frey K, Kim T, Blood J. Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimal and noninvasive probes for hepatic and first-pass CYP3A induction. Clin Pharmacol Ther. 2011 Jul;90(1):100-8.

**Kharasch 2011b** Kharasch ED, Vangveravong S, Buck N, London A, Kim T, Blood J, Mach RH. Concurrent assessment of hepatic and intestinal cytochrome P450 3A activities using deuterated alfentanil. Clin Pharmacol Ther. 2011 Apr;89(4):562-70.

**Phimmasone 2001** Phimmasone S, Kharasch ED. A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. Clin Pharmacol Ther. 2001 Dec;70(6):505-17.



## Rifampicin-Alprazolam-DDI

**Gashaw 2003** Gashaw, I., Kirchheiner, J., Goldammer, M., Bauer, S., Seidemann, J., Zoller, K., ... & Brockmöller, J. (2003). Cytochrome p450 3A4 messenger ribonucleic acid induction by rifampin in human peripheral blood mononuclear cells: correlation with alprazolam pharmacokinetics. *Clinical Pharmacology & Therapeutics*, *74*(5), 448-457.

**Schmider 1999** Schmider, J., Brockmöller, J., Arold, G., Bauer, S., & Roots, I. (1999). Simultaneous assessment of CYP3A4 and CYP1A2 activity in vivo with alprazolam and caffeine. *Pharmacogenetics*, *9*(6), 725-734.



## Rifampicin-Midazolam-DDI

**Backman 1996** Backman JT, Olkkola KT, Neuvonen PJ. Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther. 1996 Jan;59(1):7-13.

**Backman 1998** Backman JT, Kivistö KT, Olkkola KT, Neuvonen PJ. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol. 1998 Mar;54(1):53-8.

**Björkhem-Bergman 2013** Björkhem-Bergman L, Bäckström T, Nylén H, Rönquist-Nii Y, Bredberg E, Andersson TB, Bertilsson L, Diczfalusy U. Comparison of endogenous 4β-hydroxycholesterol with midazolam as markers for CYP3A4 induction by rifampicin. Drug Metab Dispos. 2013 Aug;41(8):1488-93.

**Chattopadhyay 2018** Chattopadhyay N, Kanacher T, Casjens M, Frechen S, Ligges S, Zimmermann T, Rottmann A, Ploeger B, Höchel J, Schultze-Mosgau MH. CYP3A4-mediated effects of rifampicin on the pharmacokinetics of vilaprisan and its UGT1A1-mediated effects on bilirubin glucuronidation in humans. Br J Clin Pharmacol. 2018 Dec;84(12):2857-2866.

**Chung 2006** Chung E, Nafziger AN, Kazierad DJ, Bertino JS Jr. Comparison of midazolam and simvastatin as cytochrome P450 3A probes. Clin Pharmacol Ther. 2006 Apr;79(4):350-61.

**Eap 2004** Eap CB, Buclin T, Cucchia G, Zullino D, Hustert E, Bleiber G, Golay KP, Aubert AC, Baumann P, Telenti A, Kerb R. Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity. Eur J Clin Pharmacol. 2004 Jun;60(4):237-46.

**Gorski 2003** Gorski JC, Vannaprasaht S, Hamman MA, Ambrosius WT, Bruce MA, Haehner-Daniels B, Hall SD. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin Pharmacol Ther. 2003 Sep;74(3):275-87.

**Gurley 2006** Gurley B, Hubbard MA, Williams DK, Thaden J, Tong Y, Gentry WB, Breen P, Carrier DJ, Cheboyina S. Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin. J Clin Pharmacol. 2006 Feb;46(2):201-13.

**Gurley 2008a** Gurley BJ, Swain A, Hubbard MA, Hartsfield F, Thaden J, Williams DK, Gentry WB, Tong Y. Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo. Clin Pharmacol Ther. 2008 Jan;83(1):61-9.

**Kharasch 1997** Kharasch ED, Russell M, Mautz D, Thummel KE, Kunze KL, Bowdle A, Cox K. The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. Anesthesiology. 1997 Jul;87(1):36-50.

**Kharasch 2004** Kharasch ED, Walker A, Hoffer C, Sheffels P. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. Clin Pharmacol Ther. 2004 Nov;76(5):452-66.

**Kharasch 2011** Kharasch ED, Francis A, London A, Frey K, Kim T, Blood J. Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimal and noninvasive probes for hepatic and first-pass CYP3A induction. Clin Pharmacol Ther. 2011 Jul;90(1):100-8.

**Kim 2018** Kim B, Lee J, Shin KH, Lee S, Yu KS, Jang IJ, Cho JY. Identification of ω- or (ω-1)-Hydroxylated Medium-Chain Acylcarnitines as Novel Urinary Biomarkers for CYP3A Activity. Clin Pharmacol Ther. 2018 May;103(5):879-887.

**Link 2008** Link B, Haschke M, Grignaschi N, Bodmer M, Aschmann YZ, Wenk M, Krähenbühl S. Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping. Br J Clin Pharmacol. 2008 Oct;66(4):473-84.

**Lutz 2018** Lutz JD, Kirby BJ, Wang L, Song Q, Ling J, Massetto B, Worth A, Kearney BP, Mathias A. Cytochrome P450 3A Induction Predicts P-glycoprotein Induction; Part 1: Establishing Induction Relationships Using Ascending Dose Rifampin. Clin Pharmacol Ther. 2018 Dec;104(6):1182-1190.

**Phimmasone 2001** Phimmasone S, Kharasch ED. A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. Clin Pharmacol Ther. 2001 Dec;70(6):505-17.

**Prueksaritanont 2017** Prueksaritanont T, Tatosian DA, Chu X, Railkar R, Evers R, Chavez-Eng C, Lutz R, Zeng W, Yabut J, Chan GH, Cai X, Latham AH, Hehman J, Stypinski D, Brejda J, Zhou C, Thornton B, Bateman KP, Fraser I, Stoch SA. Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A. Clin Pharmacol Ther. 2017 Apr;101(4):519-530.

**Reitman 2011** Reitman ML, Chu X, Cai X, Yabut J, Venkatasubramanian R, Zajic S, Stone JA, Ding Y, Witter R, Gibson C, Roupe K, Evers R, Wagner JA, Stoch A. Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design. Clin Pharmacol Ther. 2011 Feb;89(2):234-42.

**Shin 2013** Shin KH, Choi MH, Lim KS, Yu KS, Jang IJ, Cho JY. Evaluation of endogenous metabolic markers of hepatic CYP3A activity using metabolic profiling and midazolam clearance. Clin Pharmacol Ther. 2013 Nov;94(5):601-9.

**Shin 2016** Shin KH, Ahn LY, Choi MH, Moon JY, Lee J, Jang IJ, Yu KS, Cho JY. Urinary 6β-Hydroxycortisol/Cortisol Ratio Most Highly Correlates With Midazolam Clearance Under Hepatic CYP3A Inhibition and Induction in Females: A Pharmacometabolomics Approach. AAPS J. 2016 Sep;18(5):1254-1261.

**Szalat 2007** Szalat A, Gershkovich P, Ben-Ari A, Shaish A, Liberman Y, Boutboul E, Gotkine M, Hoffman A, Harats D, Leitersdorf E, Meiner V. Rifampicin-induced CYP3A4 activation in CTX patients cannot replace chenodeoxycholic acid treatment. Biochim Biophys Acta. 2007 Jul;1771(7):839-44.

**van Dyk 2018** van Dyk M, Marshall JC, Sorich MJ, Wood LS, Rowland A. Assessment of inter-racial variability in CYP3A4 activity and inducibility among healthy adult males of Caucasian and South Asian ancestries. Eur J Clin Pharmacol. 2018 Jul;74(7):913-920.

**Wiesinger 2020** Wiesinger H, Klein S, Rottmann A, Nowotn B, Riecke K, Gashaw I, Brudny-Klöppel M, Fricke R, Höchel J, Friedrich C. The effects of weak and strong CYP3A induction by rifampicin on the pharmacokinetics of five progestins and ethinylestradiol compared to midazolam. Clin Pharmacol Ther. 2020 Apr 10.

**Yu 2004** Yu KS, Cho JY, Jang IJ, Hong KS, Chung JY, Kim JR, Lim HS, Oh DS, Yi SY, Liu KH, Shin JG, Shin SG. Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. Clin Pharmacol Ther. 2004 Aug;76(2):104-12.



## Rifampicin-Triazolam-DDI

**Villikka 1997** Villikka K, Kivistö KT, Backman JT, Olkkola KT, & Neuvonen PJ. Triazolam is ineffective in patients taking rifampin. Clin Pharmacol Ther. 1997 Jan;61(1):8-14.



## Rifampicin-Verapamil-DDI

**Barbarash 1988** Barbarash RA, Bauman JL, Fischer JH, Kondos GT, Batenhorst RL. Near-total reduction in verapamil bioavailability by rifampin. Electrocardiographic correlates. Chest. 1988 Nov;94(5):954-9.

